

84

High Throughput Screening of a 100,000 Compound Library for Inhibitors of Influenza A Virus (H3N2)

William Severson^{1,*}, Michael McDowell¹, Lynn Rasumussen², Mindy Sosa², Subramaniam Ananthan³, James Noah¹, Lucile White², Colleen Jonsson¹

¹ Department of Biochemistry and Molecular Biology, AL, USA; ² High Throughput Screening Center, AL, USA; ³ Department of Chemistry, Southern Research Institute, Birmingham, AL 35205, USA

There are a limited number of antivirals for the control of seasonal and pandemic influenza viruses. To discover small molecules that inhibit the cytopathic effect exerted by influenza viruses, we employed our high-throughput cell-based assay (Noah et al., Antiviral Res. 2006) to screen a commercially available compound library. Using the reproducible and highly robust assay, we have screened 100,000 compounds from the ChemBridge 2 (CB2) compound library at a low and high concentration against Influenza strain A/Udm/72 (H3N2). The “hit” rate (>50% CPE inhibition of virus) for the compounds screened at 5 µg/ml and 40 µg/ml was determined to be 0.022% and 0.37%, respectively. The hits obtained in this screen were evaluated by measuring their antiviral activity, cell toxicity and selectivity in dose response experiments. Three compounds displayed moderate activity (SI₅₀ = 10–49) in reducing influenza in the presence of 5 µg/ml compound. Quite the opposite, when screening at the higher concentration, several compounds were identified that were highly active with an SI₅₀ > 50. These quantitative data provide a foundation for grouping the hits into classes of compounds with similar scaffolds for structure activity relationship (SAR) analysis and make them excellent candidates for the development of new small-molecule therapeutics.

Acknowledgement: This work was supported by contract NO1-AI-30047.

doi:10.1016/j.antiviral.2007.01.092

85

Antiviral Activity of Reverse Transcriptase Inhibitors against Porcine Endogenous Retroviruses (PERV)

Minyi Shi^{1,2,*}, Xin Wang¹, Erik De Clercq³, Sonshin Takao², Masanori Baba¹

¹ Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; ² Frontier Science Research Center, Kagoshima University, Kagoshima, Japan; ³ Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

Background: Xenotransplantation is a possible solution to the shortage of organs in transplantation. The Kagoshima strain of mini-pigs is considered to be a suitable organ donor in xenotransplantation because of its size and other favorable profiles. However, a concern about the transmission of porcine endoge-

nous retrovirus (PERV) from donor organs to recipients has been raised. Therefore, we have evaluated various reverse transcriptase (RT) inhibitors for their inhibitory effect on PERV replication in vitro.

Materials and methods: The PERV-producing cell line PK15 and the primary kidney cells from the Kagoshima strain were used for the sources of PERV. The human cell line 293T was infected with PERV and cultured in the presence of various concentrations of test compounds. After a certain incubation period, the amount of proviral DNA in the infected cells was determined by real-time PCR. The triphosphate (TP) forms of some compounds were also examined for their inhibitory effect on PERV RT activity.

Results: Among the eight RT inhibitors examined, AZT was found to be the most active against PERV. Its EC₅₀ was approximately 0.02 µM. The order of potency was AZT > PMEODAPy = PMPDAP > PMPA ≥ PMEAD > d4T (EC₅₀ = 5–10 µM). Furthermore, AZTTP proved to be a more potent inhibitor of PERV RT than d4TTP. In contrast, 3TC, 4'-ethynyl-d4T, and the nonnucleoside RT inhibitor nevirapine were inactive against PERV replication.

Conclusion: Some nucleoside HIV RT inhibitors, such as AZT, PMEODAPy, and PMPDAP, may be effective in the prevention of PERV transmission to humans upon xenotransplantation.

doi:10.1016/j.antiviral.2007.01.093

86

17-AAG, an Hsp90 Inhibitor, Suppress Hepatitis C Virus (HCV) Replication

Saneyuki Ujino^{1,*}, Kunitada Shimotohno³, Hiroshi Takaku^{1,2}

¹ Department of Life and Environmental Sciences, Chiba, Japan; ² High Technology Research Center, Chiba Institute of Technology, 2-17-1 Tsudanuma Narashino, Chiba 275-0016, Japan; ³ Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto 606-0507, Japan

Heat-shock protein 90 (Hsp90), which accounts for 1–2% of cytosolic protein, is one of the most abundant cellular chaperone proteins. It functions in a multicomponent complex of chaperone proteins including Hsp70, Hop (Hsp70 and Hsp90 organizing protein), Cdc37, Hsp40 and p23. Hsp90 is involved in the folding, activation and assembly of several proteins, known as Hsp90 client proteins. As numerous oncoproteins have been shown to be Hsp90 client proteins, Hsp90 inhibitors have become a new strategy in antitumor therapy. Geldanamycin, a classical Hsp90 inhibitor, is known as a potent antitumor agent; however, it has not been used in clinical trials because of its liver toxicity. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a new derivative of geldanamycin that shares its important biological activities but shows less toxicity.

Here, we present a new and potent strategy for the hepatitis C virus (HCV) therapy with 17-AAG, an Hsp90 inhibitor. We examine the effects of 17-AAG on full length HCV replicon cells line. The HCV RNA replication in the HCV replicon was quan-

tified by real time RT-PCR (Taq-Man) at 2 days with indicated dose (0.25 nM, 25 nM, 50 nM, and 250 nM) or with DMSO as control. Taq-Man PCR analysis showed a dose-dependent inhibition of HCV RNA replication after treatment with 17-AAG. The 17-AAG-mediated HCV replication inhibition is due to the directly interaction of Hsp90 and NS3 by immunoprecipitation. These results have exciting implications for the HCV life cycle and novel antiviral strategies.

doi:[10.1016/j.antiviral.2007.01.094](https://doi.org/10.1016/j.antiviral.2007.01.094)

87

Development of Anti-Infective Topical Microbicides

2. Quantifying Inhibition of Virus Transmission in Microbicidal Setting

Karen Watson*, Lu Yang, Robert Buckheit Jr.

ImQuest BioSciences, Inc., Frederick, MD, USA

Over 25 million people have died since the first case of AIDS was identified in 1981, and the number of people living with HIV worldwide continues to expand—from 35 million in 2001 to an estimated 40 million in 2005. In the absence of a fully effective HIV vaccine, topical microbicides represent an important potential strategy for preventing the transmission of HIV through sexual intercourse, the predominant mode of HIV transmission worldwide. Although a comprehensive understanding of HIV transmission has not yet emerged, it is currently thought that virus transmission occurs rapidly and is likely the result of infection of monocyte-derived cells in the vaginal mucosa by CCR5-tropic viruses. Transmission of virus in the microbicide setting will require agents which prevent virus entry, fusion, reverse transcription, or other pre-integrative events, or agents which directly inactivate HIV or modulate the target cells to render them uninfected. In vitro assays which are typically utilized to evaluate the ability of a microbicide to prevent virus transmission utilize adherent cells (MAGI or GHOST cells) or cells more relevant to the development of anti-HIV therapeutics (PBMcs) and quantify virus production following transmission at short time intervals following infection. We have modified a virus sterilization assay to evaluate virus transmission over the course of 30 days of culture in the presence and absence of microbicidal compounds. These assays effectively demonstrate that the transmission inhibition capacity of microbicides is dramatically over-estimated in the short-term assays. Data obtained in this microbicidal transmission assay define the concentration of the microbicide required to completely prevent the transmission of virus to target cells and is likely the minimal concentration of the microbicide that will need to be provided in a final formulated product. Further the assay can be used to define the effects of viral multiplicity of infection and the effects of rare populations of resistant virus strains on transmission events. The results of our studies with a variety of potential microbicides being developed in our laboratories will be presented.

doi:[10.1016/j.antiviral.2007.01.095](https://doi.org/10.1016/j.antiviral.2007.01.095)

88

Development of Anti-Infective Topical Microbicides

1. Effects of Seminal and Vaginal Fluids and Other Additives on Viral Infection and Drug Efficacy

Karen Watson*, Lu Yang, Robert Buckheit Jr.

ImQuest BioSciences, Inc., Frederick, MD, USA

Over 25 million people have died since the first case of AIDS was identified in 1981, and the number of people living with HIV worldwide continues to expand from 35 million in 2001 to an estimated 40 million in 2005. Almost 5 million people worldwide became newly infected with HIV and an estimated 3.8 million human deaths were attributed to AIDS in 2005. In the absence of a fully effective HIV vaccine, topical microbicides represent an important potential strategy for preventing the transmission of HIV through sexual intercourse, the predominant mode of HIV transmission worldwide. The number of women with HIV infection and AIDS has been increasing steadily worldwide, accounting for 46% of all adults living with HIV worldwide, and for 57% in sub-Saharan Africa. Thus the dynamics of the epidemic demand the development of safe, effective and acceptable female-controlled chemical and physical barrier methods, including topical microbicides, to reduce HIV transmission. Although a complete understanding of virus infection of cells in the vaginal vault has yet to emerge in the microbicide field, it is accepted that infection likely occurs inefficiently in the first moments following the introduction of the viral inoculum in the vagina. In order to further explore the biology of infection, we have evaluated the effects of seminal plasma, vaginal fluids, other mucopolysaccharide additives and vaginal pH on both the infectivity of HIV and the efficacy of microbicides being developed for clinical use. Each of these additives or environmental changes might be expected to play roles alone and in combination with one another on the efficiency of virus transmission. The effects of these environmental conditions can be modeled and quantified in vitro. Our results would indicate that authentic seminal plasma has a major impact on the ability of HIV to transmit to target cells in assays which mimic the vaginal environment. Vaginal fluids have less effect on transmission but both biological fluids can affect the activity of potential microbicides in both negative and positive ways. We will present the results of studies demonstrating the impact of biological fluids on virus transmission and microbicide efficacy.

doi:[10.1016/j.antiviral.2007.01.096](https://doi.org/10.1016/j.antiviral.2007.01.096)